896
Views
13
CrossRef citations to date
0
Altmetric
Review Article

A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention

, &
Pages 418-427 | Accepted 07 Jun 2010, Published online: 16 Jul 2010

References

  • Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-1619
  • Lloyd-Jones D, Adams R, Canethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181
  • Luengo-Fernández R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384-1389
  • Pestana JA, Steyn K, Leiman A, et al. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S Afr Med J 1996;86:679-684
  • Azambuja MI, Foppa M, Maranhão MF, et al. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arg Bras Cardiol 2008;91:148-155, 163-171
  • Zhai Y, Hu JP, Kong LZ, et al. [Economic burden of coronary heart disease and stroke attributable to hypertension in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:744-747
  • Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370:1929-1938
  • US Preventive Services Task Force (USPSTF). Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009;150:396-404
  • Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-2414
  • Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;32:1129-1135
  • Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-316
  • Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762
  • Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
  • The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-241
  • Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-3272
  • Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373:1849-1860
  • Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006;98:746-750
  • Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313
  • World Health Organization. Prevention of Cardiovascular Disease. Guidelines for assessment and management of cardiovascular risk. 2007. Available at: http://www.who.int/cardiovascular_diseases/guidelines/Prevention_of_Cardiovascular_Disease/en/index.html. Last Accessed 01 March, 2010
  • Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
  • Khan NA, Hemmelgarn B, Herman RJ, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2—therapy. Can J Cardiol 2009;25:287-298
  • American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010;33(Suppl 1):S11-61
  • Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141
  • Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840
  • Leung WY, So WY, Stewart D, et al. Lack of benefits for prevention of cardiovascular disease with aspirin in type 2 diabetic patients—a longitudinal observational study. Cardiovasc Diabetol 2009;8:57
  • De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
  • Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;77:211-218
  • Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-2306
  • Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes Study. Diabetes Care 2010;33:317-321
  • Lamotte M, Annemans L, Evers T, et al. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-169
  • Lamotte M, Pinol C, Brotons C, et al. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease]. Rev Esp Cardiol 2006;59:807-815
  • Tsutani K, Igarashi A, Fujikawa K, et al. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med 2007;46:157-162
  • Benedict A, Manson SC, Pan F, et al. US budget impact of increasing low dose aspirin usage for primary and secondary prevention of cardiovascular disease. Presented at the American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference, Washington, DC, Apr 23--25, 2009, Poster 75
  • Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-686
  • Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country – the case of Tanzania. Cost-Eff Resour Alloc 2007;5:3
  • Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008;117:2875-2883
  • Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007;167:290-295
  • Algra A, Greving JP. Aspirin in primary prevention: sex and baseline risk matter. Lancet 2009;373:1821-1822
  • Moeremans K, Lamotte M, Wittrup-Jensen K. The health economic value of aspirin in the primary prevention of cardiovascular disease in diabetic patients. Presented at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, LA, Jun 5--9, 2009. Abstract 44-OR
  • Franco OH, der Kinderen AJ, De Laet C, et al. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care 2007;23:71-79
  • Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
  • Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modeling study. Eur J Cardiovasc Prev Rehab 2006;13:523-528
  • Neyt M, De Laet C, Van Brabandt H, et al. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol 2009;64:1-10
  • Marshall T. Coronary heart disease prevention: insights from modeling incremental cost effectiveness. BMJ 2003;327:1264
  • Annemans L, Lamotte M, Kubin M, et al. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. Int J Clin Pract 2006;60:1129-1137
  • McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-638
  • Saini SD, Schoenfeld P, Fendrick AM, et al. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008;168:1684-1690
  • Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease. PLoS Med 2005;12:e353
  • Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world: disease burden can be lowered with cost-effective interventions, especially by reducing the use of tobacco around the world. Health Aff (Millwood) 2007;26:13-24
  • Sartore ME, Kamal KM. Costs and thresholds in cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:1455-1456

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.